Literature DB >> 19383854

The role of floxuridine in metastatic liver disease.

Derek G Power1, Nancy E Kemeny.   

Abstract

Liver metastases are mainly supplied by the hepatic artery. Sustained high levels of intratumoral drug are achievable with certain drugs given via the hepatic artery. Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction. HAI FUDR has consistently shown higher response rates than systemic chemotherapy alone, and some studies have shown a survival advantage. HAI FUDR in combination with systemic chemotherapy has evolved over the years and may be used in palliative, neoadjuvant, and adjuvant settings. The dramatic responses observed with HAI FUDR plus modern era systemic chemotherapy offer the possibility of resection and cure in selected patients. The high hepatic extraction of FUDR limits systemic side effects. Toxicity includes biliary and gastrointestinal ulcers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383854     DOI: 10.1158/1535-7163.MCT-08-0709

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  28 in total

1.  Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer.

Authors:  Guo-Liang Yao; Yong-Gang Fan; Jing-Ming Zhai; Bao-Sai Lu; Kai-Long Liu
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer.

Authors:  Ozkän Kanat; Alexandra Gewirtz; Nancy Kemeny
Journal:  J Gastrointest Oncol       Date:  2012-06

Review 3.  Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.

Authors:  Alexandre Doussot; Nancy E Kemeny; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2015-07-27

4.  Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

Authors:  Amelia M Huehls; Jill M Wagner; Catherine J Huntoon; Liyi Geng; Charles Erlichman; Anand G Patel; Scott H Kaufmann; Larry M Karnitz
Journal:  Cancer Res       Date:  2011-05-25       Impact factor: 12.701

5.  Horizontally acquired genes in early-diverging pathogenic fungi enable the use of host nucleosides and nucleotides.

Authors:  William G Alexander; Jennifer H Wisecaver; Antonis Rokas; Chris Todd Hittinger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-29       Impact factor: 11.205

Review 6.  Meeting the biologic challenge of colorectal metastases.

Authors:  Harold J Wanebo; Mark LeGolvan; Philip B Paty; Sukamal Saha; Markus Zuber; Michael I D'Angelica; Nancey E Kemeny
Journal:  Clin Exp Metastasis       Date:  2012-10-10       Impact factor: 5.150

Review 7.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

8.  A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.

Authors:  Apostolia M Tsimberidou; Siqing Fu; Chaan Ng; Jo Ann Lim; Sijin Wen; David Hong; Jennifer Wheler; Agop Y Bedikian; Cathy Eng; Michael Wallace; Luis H Camacho; Razelle Kurzrock
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

9.  Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.

Authors:  Amelia M Huehls; Jill M Wagner; Catherine J Huntoon; Larry M Karnitz
Journal:  Mol Pharmacol       Date:  2012-07-25       Impact factor: 4.436

10.  Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.

Authors:  S M S Ng; J S P Sioson; J M Yap; F M Ng; H S V Ching; J W P Teo; R Jureen; J Hill; C S B Chia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.